SouthState Corp’s Agios Pharmaceuticals AGIO Stock Holding History

SouthState Corp’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4	Closed	-$117	–	1594
2025 Q1	$117	Buy	+4	New	+$133	﹤0.01%	1679

Other funds holding AGIO

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SouthState Corp's AGIO Position: Q2 2025 in Review

SouthState Corp sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 4 shares — an estimated $117 sold.

SouthState Corp first reported a position in AGIO in Q1 2025 and held it in 1 quarter. The position peaked at $117 in Q1 2025. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

SouthState Corp reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 4 Agios Pharmaceuticals shares in Q2 2025, an estimated $117.
SouthState Corp first reported a position in Agios Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SouthState Corp's Agios Pharmaceuticals position peaked at $117 in Q1 2025.
214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.